When a new cancer therapy hits the market, it arrives with the promise of high efficacy and manageable side effects. But for many patients with relapsed diffuse large B-cell lymphoma (rDLBCL), that promise often fails to materialize in the clinic. The reason isn't necessarily the drug itself, but the massive chasm between the "ideal" patients who participated in clinical trials and the real-world patients who receive the treatment afterward.

A study published in Leukemia & Lymphoma by researchers at the Olivia Newton-John Cancer Research Institute (ONJCRI) has quantified this disconnect. By analyzing 180 patients against the eligibility criteria of seven landmark trials for novel therapies, the team found that 52 percent of real-world relapse episodes would have been excluded from the very trials that secured the drugs' approval. Not a single patient in the study met the criteria for all seven trials.

The Myth of the 'Average' Patient

Clinical trials are designed to be controlled environments. They prioritize safety and the ability to isolate a drug's effect, which often leads to restrictive eligibility criteria—median requirements of 39 distinct criteria per trial, according to the ONJCRI research. These criteria often include strict thresholds for organ function, specific definitions of "measurable disease," and limitations on prior treatments.

Once a drug is approved, however, the regulatory "guardrails" loosen significantly. Physicians in routine practice prescribe these therapies to a much broader, more complex population—patients who are older, have multiple comorbidities, or have undergone more aggressive prior treatments. When these patients receive drugs tested only on the "best" candidates, they often face higher rates of toxicity and lower efficacy than the trial data suggested.

Why the Disconnect Matters

"Only the 'best' patients are eligible for these clinical trials," says Dr. Elizabeth Goodall, a practicing hematologist and lead researcher on the study. "Once the treatment has been approved by the regulatory bodies, there is far less regulation over which patients receive the treatment in the clinics. This can expose patients to unexpected toxicity and lower than expected treatment efficacy."

This extrapolation of data is standard practice, but it carries hidden risks. When clinicians use trial data to counsel patients on what to expect, they are often relying on a best-case scenario that may not apply to the person sitting in the exam chair. The study suggests that the hematology community needs to be more skeptical of trial cohorts when applying their findings to the general population.

Key Takeaways

  • Over half of real-world rDLBCL patients would have been ineligible for the landmark trials that approved their current treatments.
  • Restrictive trial criteria—often requiring dozens of specific health benchmarks—create a "trial gap" that masks potential toxicity for broader patient groups.
  • Clinicians should look beyond trial "success rates" and carefully weigh the specific eligibility criteria against a patient's individual health profile before starting new therapies.

What Experts Say

Researchers are now calling for a shift in how registrational trials are conducted. While early-stage trials must remain rigorous to ensure safety, experts argue that later-stage trials should adopt more inclusive and permissive criteria. By better reflecting the characteristics of real-world populations, these trials could provide a more accurate picture of how a drug will perform once it reaches the broader public.

For patients and their families, the next step is a more nuanced conversation with their care team. As the next generation of targeted therapies and CAR-T treatments move through the pipeline, the focus must shift from simply asking if a drug is "approved" to asking how well the trial population actually mirrors the patient’s own medical history. The next major oncology conference in late 2026 will likely see this data spark a broader debate on whether regulatory bodies should mandate more diverse trial cohorts as a condition for approval.